Q1 2023 Aleon Regulatory Frontiers Newsletter

February 2023

Q1 2023 Aleon Regulatory Frontiers Newsletter

As a regulatory affairs consulting company, we fully understand that staying informed about regulatory affairs in the pharmaceutical industry can be quite challenging. Our goal with this quarterly newsletter is to keep you up-to-date as you navigate the complex world of regulatory affairs. In this edition, you will find the following articles prepared directly by Aleon staff members: - Is a Pre-IND Meeting Necessary for your Program? - Increased Focus for Orphan Drug Development - eCTD Submissions in China, What You Need to Know - IND Submissions in Multiple Markets - FDA Drug Development Outlook in 2023 & Beyond We hope that you find this information useful, and we truly look forward to staying connected and serving you throughout your journey.

Click to view: Aleon Regulatory Frontiers Q1 2023